SS-31, also known as elamipretide or MTP-131, is an aromatic-cationic tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin. Across the published clinical program, amounts studied in human trials have ranged from subcutaneous injections in the tens of milligrams for genetic mitochondrial disease to intravenous infusions in heart attack and heart failure models, with the amount and route set by the trial design, not by a single standard regimen.
| Key fact | Value | Source |
|---|---|---|
| Compound class | Aromatic-cationic tetrapeptide, D-Arg-2',6'-dimethyltyrosine-Lys-Phe-NH2 | Zhao et al. 2004, J Biol Chem |
| Primary target | Cardiolipin in the inner mitochondrial membrane | Birk et al. 2013, J Am Soc Nephrol |
| Disease programs with published trial data | Barth syndrome, primary mitochondrial myopathy, chronic heart failure, ST-elevation myocardial infarction reperfusion injury | Trial publications cited below |
| Routes reported across the program | Subcutaneous injection (chronic studies), intravenous infusion (acute cardiac studies) | Trial publications cited below |
| Common endpoints across trials | 6-minute walk distance, muscle strength, ejection fraction, infarct size, mitochondrial respiration | Trial publications cited below |
What is elamipretide and how does it interact with mitochondria?
Elamipretide was characterized in cell and isolated-mitochondria work by Zhao and colleagues, who showed that the peptide concentrates several-thousand-fold in the inner mitochondrial membrane because of its alternating cationic and aromatic residues, then binds cardiolipin through electrostatic and hydrophobic interactions. That binding stabilizes cristae structure and limits the drop in mitochondrial membrane potential that follows an oxidative stress. The mechanism work used isolated cardiac mitochondria and cultured cells, not whole animals or humans, which is why it sits earliest in the Study table below.
What amounts were studied in the Barth syndrome trial program?
Barth syndrome is a rare X-linked disorder of cardiolipin remodeling caused by variants in the TAZ gene, producing skeletal myopathy, cardiomyopathy and exercise intolerance. The published Barth syndrome program used a randomized, double-blind, placebo-controlled crossover design followed by an open-label extension, administering elamipretide by daily subcutaneous injection and tracking the 6-minute walk distance and knee extensor strength as primary physical-function endpoints, alongside plasma pharmacokinetic sampling. The amount and schedule used in that trial are reported in the Study table rather than restated here, since the figure applies only inside that specific crossover design.
What amounts were studied in the heart failure trial?
The chronic heart failure program tested elamipretide by intravenous infusion in adults with reduced ejection fraction, measuring changes in left ventricular end-systolic and end-diastolic volumes by echocardiography after a defined infusion period. The trial also tracked standard safety labs and vital signs across the infusion visits, since an intravenous mitochondria-targeted peptide given to a cardiac population requires close monitoring of blood pressure and renal function.
What amounts were studied in primary mitochondrial myopathy?
Primary mitochondrial myopathy trials enrolled adults with genetically confirmed mitochondrial DNA or nuclear mutations causing skeletal muscle weakness and fatigue. The dose-escalation design moved subjects through ascending subcutaneous amounts while tracking the 6-minute walk distance, a fatigue severity scale and plasma and urine biomarkers of oxidative stress. A later, larger trial in the same population used a fixed subcutaneous amount selected from the escalation data to test whether functional gains held up over a longer treatment window.
How do the acute cardiac reperfusion studies differ in design?
The reperfusion-injury studies are mechanistically distinct from the chronic disease trials: elamipretide was infused intravenously around the time of primary percutaneous coronary intervention in ST-elevation myocardial infarction, with infarct size by cardiac MRI or biomarker-based estimation as the primary endpoint rather than a strength or walk-distance measure. This acute, short-infusion design reflects the hypothesis that preserving mitochondrial membrane potential during the minutes of reperfusion limits the burst of oxidative damage that follows restored blood flow, which is a different biological question than the months-long chronic dosing used in Barth syndrome and mitochondrial myopathy.
What do the preclinical models show about amount and route?
Before any human trial, elamipretide's cardioprotective and renal-protective effects were established in rodent ischemia-reperfusion models. Birk and colleagues used a rat model of renal ischemia-reperfusion injury to show that short-course dosing around the ischemic event preserved cardiolipin content and mitochondrial respiratory function in kidney tissue, supporting the rationale for testing the compound around acute ischemic events in humans. These preclinical amounts and routes, reported exactly as the papers state them, appear in the Study table.
| Study | Model and n | Amount and route (as reported) | Endpoint | Finding |
|---|---|---|---|---|
| Zhao et al. 2004 (PubMed) | Isolated cardiac mitochondria and cultured cells | Nanomolar to low micromolar concentrations applied directly to isolated mitochondria, in vitro | Mitochondrial swelling, cytochrome c release, membrane potential | Peptide concentrated in the inner membrane and limited swelling and cytochrome c loss after an oxidative challenge |
| Birk et al. 2013 (PubMed) | Rat, unilateral renal ischemia-reperfusion, n reported by treatment group in the paper | Subcutaneous injection beginning at the time of reperfusion, short course | Cardiolipin content, mitochondrial oxygen consumption, serum creatinine | Treated kidneys showed preserved cardiolipin and better recovery of mitochondrial respiration than vehicle |
| Sabbah et al. 2016 (PubMed) | Dog, coronary microembolization heart failure model | Chronic subcutaneous administration over several weeks | Left ventricular ejection fraction, mitochondrial respiration in biopsied myocardium | Treated animals showed improved ejection fraction and mitochondrial oxygen consumption versus untreated animals |
| Gibson et al. 2016, EMBRACE-STEMI (PubMed) | Human, ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention | Short intravenous infusion started before reperfusion | Infarct size by cardiac biomarker area-under-the-curve | No significant reduction in infarct size versus placebo in the primary analysis |
| Daubert et al. 2017, PEDAL-HF (PubMed) | Human, chronic systolic heart failure, randomized placebo-controlled | Intravenous infusion given over a single defined visit | Left ventricular end-systolic and end-diastolic volumes by echocardiography | No statistically significant change in ventricular volumes versus placebo at the primary timepoint |
| Karaa et al. 2018, MMPOWER (PubMed) | Human, primary mitochondrial myopathy, randomized dose-escalation, n in the low dozens | Ascending subcutaneous injections across sequential cohorts | 6-minute walk distance, fatigue severity scale, oxidative stress biomarkers | Subjects in active-treatment cohorts showed a trend toward improved walk distance and reduced fatigue scores versus placebo |
| Thompson et al. 2021, TAZPOWER (PubMed) | Human, genetically confirmed Barth syndrome, randomized double-blind crossover plus open-label extension | Daily subcutaneous injection during each crossover period and the extension | 6-minute walk distance, knee extensor strength, plasma pharmacokinetics | Walk distance and muscle strength improved during active treatment periods relative to placebo periods |
How is elamipretide handled in a research setting?
Lyophilized elamipretide ships as a sealed powder and is reconstituted with an appropriate diluent immediately before use in a study, with the reconstituted solution kept cold and used within the stability window noted on the lot's certificate of analysis. The math for getting from a lyophilized vial to a working concentration follows the same volume-and-concentration approach used for any lyophilized research peptide, covered step by step in reconstituting lyophilized peptides, and the identity and purity figures that should accompany every lot are explained in how to read a peptide certificate of analysis.
Why do the amounts differ so much between trials?
The amount and route in each elamipretide trial tracks the biological question being asked, not a single agreed figure. Acute reperfusion studies used short intravenous infusions timed to a procedure measured in minutes, chronic muscle and cardiac disease trials used daily or near-daily subcutaneous injections sustained over weeks to months, and the dose-escalation trial in mitochondrial myopathy was explicitly designed to compare cohorts at different amounts before a fixed amount was carried into later testing. Readers comparing figures across these papers should match the amount to its specific trial design rather than treating any single number as representative of the compound generally.
For background on elamipretide's structure and its place among other mitochondria-targeted research peptides, see what is SS-31 (elamipretide) and the comparison in mitochondrial research compounds: NAD+, MOTS-c and SS-31 compared. SS-31 research material is available as SS-31 for laboratory use.
Frequently asked questions
Is elamipretide the same compound as SS-31?
Yes. SS-31 is the laboratory designation from the Szeto-Schiller series of aromatic-cationic peptides, and elamipretide (also written MTP-131) is the name used once the compound entered clinical development. Both terms refer to the same tetrapeptide sequence.
Were the Barth syndrome and heart failure trials testing the same amount?
No. The published trials used different routes (subcutaneous for the chronic Barth syndrome and mitochondrial myopathy programs, intravenous for the acute cardiac programs) and different schedules, reflecting the different time course of each disease model. The specific figures reported in each paper are listed in the Study table above and should not be transferred between trial designs.
Did the cardiac reperfusion trials meet their primary endpoint?
The published reperfusion-injury trial in ST-elevation myocardial infarction did not show a statistically significant reduction in infarct size on its primary analysis, while the chronic heart failure trial did not show a significant change in ventricular volumes at its primary timepoint. The mitochondrial myopathy and Barth syndrome programs reported functional improvements on walk distance and strength measures during active treatment.
What model organisms appear earliest in the elamipretide literature?
Isolated mitochondria and cultured cells were used to characterize the compound's membrane-binding behavior before any animal work, and rodent ischemia-reperfusion models followed to test whether that membrane effect translated into preserved organ function after an ischemic event.
What endpoints are common across the mitochondrial myopathy and Barth syndrome trials?
Both programs used the 6-minute walk distance as a functional endpoint and included a muscle strength measure, reflecting the shared skeletal-muscle phenotype in both conditions even though the underlying genetics differ.
Does the published literature describe elamipretide for human use outside a trial?
No. Every figure in this article comes from published trial and preclinical reports. Homegrown Peptides sells SS-31 strictly for laboratory research, not for administration to people or animals outside a study.
Where can I check the purity and identity of a research SS-31 lot?
Every research lot should ship with a certificate of analysis reporting identity by mass spectrometry and purity by HPLC. The fields to check and what they mean are explained in how to read a peptide certificate of analysis.
References
- Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-34690. PubMed PMID 15178689.
- Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261. PubMed PMID 23813215.
- Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9(2):e002206. PubMed PMID 26899020.
- Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous elamipretide on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303. PubMed PMID 26746634.
- Daubert MA, Yow E, Dunn G, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(12):e004389. PubMed PMID 29189509.
- Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221. PubMed PMID 29618625.
- Thompson WR, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478. PubMed PMID 33093622.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



